Key Drivers
- Strong liquidity
- Deep losses
- Negative cash flow
AIAI Summary
IDYA's investment case has materially improved from a cash-rich pipeline bet to a near-term commercialization story thanks to OptimUM-02 and the FDA's RTOR path, but the stock still hinges on successful NDA execution and launch of darovasertib because the market is not yet pricing in that de-risking.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Strong liquidity
- •Deep losses
- •Negative cash flow
IDYA has a very strong, low-debt balance sheet with ample cash and investments, but persistent losses, negative free cash flow, and weak operating efficiency mean the stock is supported more by assets than by earnings.
Price Behavior
Key Price Behavior Insights:
- •Bearish trend
- •Tight range
- •Shallow bounces
IDYA remains in a bearish trend after falling about 17% over the last month, but the recent tight $28-$29.1 consolidation suggests a short-term base may be forming unless it can reclaim $29.1.
Recent decline flattened into a narrow $28-$29.1 consolidation after the $28.05 low
Sentiment & News
Key News Insights:
- •FDA review
- •Trial success
- •Cash runway
IDEAYA's darovasertib program advanced meaningfully with FDA Real-Time Oncology Review and a successful OptimUM-02 readout, supporting an H2 2026 NDA filing path despite a quarterly loss, as the company retains a strong cash runway into 2030.
The news is moderately positive for IDEAYA, as regulatory and clinical momentum outweigh near-term earnings weakness and support the stock's commercialization outlook
Similar Companies in Healthcare
Other companies in the same sector with AI ratings